Catheter Ablation in Patients With End-Stage Heart Failure and Atrial Fibrillation: Two-Year Follow-Up of the CASTLE-HTx Trial

Christian Sohns; Maximilian Moersdorf; Nassir F. Marrouche; Leonard Bergau; Angelika Costard‐Jäckle; Harry J.G.M. Crijns; Henrik Fox; Gerhard Hindricks; Nikolaos Dagres; Samuel Sossalla; René Schramm; Thomas Fink; Mustapha El Hamriti; Vanessa Sciacca; Maxim Didenko; Frank Konietschke; Volker Rudolph; Jan Gummert; Jan G.P. Tijssen; Philipp Sommer

doi:10.1161/circulationaha.124.071517

Key result

Study evaluates two-year catheter ablation outcomes in end-stage HF and AF.

Key Points

To evaluate the two-year efficacy and safety of catheter ablation compared with standard medical therapy in patients with end-stage heart failure and concomitant atrial fibrillation.
Follow-up analysis of the randomized controlled CASTLE-HTx trial comparing catheter ablation with medical therapy.
Included candidates with end-stage heart failure and symptomatic atrial fibrillation evaluated for heart transplantation.
Outcomes tracked all-cause mortality, urgent heart transplantation, and ventricular assist device implantation across two years.
Catheter ablation sustained a significant reduction in the composite primary endpoint of all-cause death, urgent heart transplantation, or left ventricular assist device implantation.
Patients assigned to ablation maintained lower recurrence of atrial fibrillation and reduced disease progression compared with medical therapy alone.

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

Provides two-year ablation outcomes in end-stage HF with AF; extends limited data but leaves open need for randomized trials.

Abstract

Sohns C, Moersdorf M, Marrouche NF, et al. Catheter Ablation in Patients with End-Stage Heart Failure and Atrial Fibrillation: Two-year Follow-up of the CASTLE-HTx Trial. Circulation. 2024.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Sohns et al. (2024) studied this question. Catheter ablation outcomes at a two-year follow-up were evaluated in patients with end-stage heart failure and atrial fibrillation.

synapsesocial.com/papers/6aa3770fe39e00092d1a9e1b https://doi.org/10.1161/circulationaha.124.071517

View Full Paper

Ask AI

Bookmark

Share

Catheter Ablation in Patients With End-Stage Heart Failure and Atrial Fibrillation: Two-Year Follow-Up of the CASTLE-HTx Trial

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Catheter Ablation in Patients With End-Stage Heart Failure and Atrial Fibrillation: Two-Year Follow-Up of the CASTLE-HTx Trial

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading